Reversal of Multidrug Resistance by Apolipoprotein A1-Modified Doxorubicin Liposome for Breast Cancer Treatment

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Multidrug resistance (MDR) significantly limits chemotherapy efficacy.
• Overexpression of p-glycoprotein (P-gp) and altered apoptosis are key MDR mechanisms.
• Novel drug delivery systems are needed to overcome MDR in cancer therapy.

Purpose of the Study:

• To develop Apolipoprotein A1 (ApoA1)-modified cationic liposomes for doxorubicin (Dox) delivery.
• To evaluate the efficacy of ApoA1-liposomes in overcoming MDR in cancer models.
• To assess the safety profile of the novel drug delivery system.

Main Methods:

• Fabrication of ApoA1-modified cationic liposomes encapsulating Dox.
• In vitro evaluation of drug uptake and therapeutic effects in MCF-7/ADR cells.
• In vivo assessment of anti-tumor efficacy and organ toxicity in 4T1 subcutaneous xenograft models.

Main Results:

• ApoA1-liposomes demonstrated enhanced Dox uptake and superior therapeutic effects compared to free Dox and unmodified liposomes in MDR cells.
• The liposomal formulation facilitated burst drug release at the tumor site, improving anti-tumor activity.
• ApoA1-lip/Dox treatment exhibited reduced cardiotoxicity and organ-specific adverse effects in vivo.

Conclusions:

• ApoA1-modified liposomes are a promising strategy for reversing multidrug resistance in cancer.
• This delivery system enhances chemotherapeutic efficacy while minimizing systemic toxicity.
• The developed liposomes offer a potential breakthrough for more effective and safer cancer treatment.